Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bavarian Nordic R/I ADR
(OP:
BVNRY
)
10.30
+0.12 (+1.18%)
Streaming Delayed Price
Updated: 10:27 AM EDT, Apr 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bavarian Nordic R/I ADR
< Previous
1
2
3
Next >
Experts Cast Doubt On Dependence On Monkeypox Vaccine Amid Limited Trial Data, Supply Crunch
↗
August 23, 2022
The only FDA-approved monkeypox vaccine from Bavarian Nordic A/S (OTC: BVNY) is in short supply.
Via
Benzinga
Applied DNA Seeks Approval For PCR-Based Monkeypox Virus Test
↗
August 19, 2022
Via
Benzinga
Bavarian Nordic Recruits US Firm For Packaging Services For Its Monkeypox Vaccine
↗
August 19, 2022
Via
Benzinga
Biden Officials Seek To Boost Supply For Monkeypox Vaccines, Treatment
↗
August 18, 2022
Top Biden administration officials are poised to lay out new steps to accelerate the U.S. response amid the spread of monkeypox and demand for vaccines & treatments.
Via
Benzinga
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
↗
August 17, 2022
These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up.
Via
InvestorPlace
Bavarian Nordic's Monkeypox Vaccine Gets Thumbs Up From EU Regulator
↗
July 22, 2022
Via
Benzinga
EU, Bavarian Nordic Ink Supply Pact For 110,000 Monkeypox Vaccines
↗
June 14, 2022
Via
Benzinga
The Only Monkeypox Vaccine Maker Finds It Difficult To Meet Accelerating Demand
↗
August 17, 2022
Bavarian Nordic A/S (OTC: BVNKF), the only company with an approved vaccine for monkeypox, said it’s no longer sure it can meet demand as cases continue to rise worldwide,
Via
Benzinga
Plan To Extend Supply Of Monkeypox Vaccine On Cusp Of Emergency Clearance: Report
↗
August 09, 2022
A plan to extend the limited supply of monkeypox vaccine in order to provide additional doses may soon be receiving emergency clearance by U.S. health officials.
Via
Benzinga
3 Monkeypox Stocks to Buy as Biden Declares Public Health Emergency
↗
August 05, 2022
Monkeypox stocks are about to rise now that the White House has declared the virus a public health emergency. Here are the stocks to watch.
Via
InvestorPlace
VRAX Stock Alert: Why Is Virax Biolabs Up 120% Today?
↗
August 01, 2022
With monkeypox infections rising, Virax Biolabs’ PCR test for the underlying virus is bolstering sentiment for VRAX stock.
Via
InvestorPlace
Monkeypox Stocks On The Move: What Investors Should Know About The Outbreak
↗
August 01, 2022
The World Health Organization has declared the 2022 outbreak of monkeypox a global health emergency. The monkeypox crisis isn't as severe as the COVID-19 pandemic, but it has a number of health care...
Via
Benzinga
Why Is SIGA Technologies (SIGA) Stock Plunging 23% Today?
↗
July 29, 2022
SIGA stock is sinking lower after the FDA released a report, stating that TPOXX has not demonstrated efficacy in humans against monkeypox.
Via
InvestorPlace
Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Health Emergency
↗
July 25, 2022
Drugs and vaccines used against smallpox are seen as the first line of defense against the rising tide of monkeypox infections.
Via
InvestorPlace
SIGA Stock Soars as WHO Declares Monkeypox Global Health Emergency
↗
July 25, 2022
It's not every day that SIGA stock trends in the financial media, but today vaccine stocks are in focus due to the spread of monkeypox.
Via
InvestorPlace
Bavarian Nordic's Monkeypox Vaccine Scores EU Approval As WHO Declares Global Health Emergency
↗
July 25, 2022
Via
Benzinga
Benzinga Before The Bell: Snap's Dismal Earnings, Amazon's Healthcare Foray, Robinhood Moves 41B Dogecoin Into Single Wallet And Other Top Financial Stories Friday, July 22
↗
July 22, 2022
Reuters
Via
Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
↗
July 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine
↗
July 18, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Bavarian Nordic Inks Multiple Supply Pact For Its Monkey pox Vaccine, Updates FY22 Guidance
↗
July 18, 2022
Via
Benzinga
Lawmaker Warns San Francisco Faces 'Public Health Mess' Over Monkeypox Vaccine Shortage
↗
July 14, 2022
A California state legislator representing the Bay Area declared San Francisco is "veering toward a public health mess" after the city’s Department of Public Health acknowledged it is running out of...
Via
Benzinga
Quest Diagnostics Unveils Monkeypox Test: What You Need To Know
↗
July 13, 2022
Quest Diagnostics (NYSE: DGX) has announced the nationwide availability of a lab-developed, automated molecular diagnostic test to identify if a person is infected with monkeypox.
Via
Benzinga
20% Of US Monkeypox Cases Are In This City
↗
July 08, 2022
New York City has become the monkeypox capital of the U.S., with nearly 20% of the nation’s reported cases. What Happened: According to the New York Post, the city recorded 119 cases as of Wednesday....
Via
Benzinga
Monkeypox Stocks BVNRY, EBS, CMRX, SIGA Heat Up on U.S. Vaccine Stockpile
↗
June 29, 2022
Pharmaceutical companies that make vaccines against monkeypox are getting attention as demand for treatments against the virus grow.
Via
InvestorPlace
White House Outlines New Monkeypox Vaccine Strategy: What You Need To Know
↗
June 29, 2022
Via
Benzinga
Bavarian Nordic Launches COVID-19 Booster Study To Compare Against Pfizer/BioNTech Shot
↗
June 16, 2022
Via
Benzinga
Morning Brief: Top Financial Stories Dominating on Tuesday, June 14
↗
June 14, 2022
CNBC
Via
Benzinga
7 Monkeypox Stocks That May Take Off in Q2
↗
June 09, 2022
SIGA Technologies (SIGA) may lead on the list of Monkeypox stocks that could soar, but Bavarian Nordic seems to be leading the sales race.
Via
InvestorPlace
Why Is AIkido Pharma (AIKI) Stock Up 1,400%?
↗
June 07, 2022
AIkido Pharma (AIKI) stock is skyrocketing on Tuesday but it's not due to any positive news from the biotechnology company.
Via
InvestorPlace
Bavarian Nordic (BVNRY) Stock Gets a Boost From New Canadian Contract
↗
June 07, 2022
Bavarian Nordic (BVNRY) stock is rising higher on Tuesday after announcing a new deal with Canada to purchase one of its vaccines.
Via
InvestorPlace
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.